Lung Carcinoma — Trials

Lung Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

7,788 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,127
Recruiting: 1,127
Ph III recruiting: 164
Growth YoY: +1.4%
Industry share: 43%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,177)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07783009	An Expanded Access Program to Provide Divarasib to Participants With Previously Treated KRAS G12c-Positive Advanced or Metastatic Non-Small Cell Lung Cancer	temporarily not available	—	—	Genentech, Inc.INDUSTRY	0	Sep 14, 2026	clinicaltrials
NCT04830202	Expanded Access to Telisotuzumab Vedotin	temporarily not available	—	—	AbbVieINDUSTRY	0	May 13, 2026	clinicaltrials